Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vicente Boix

Showing results (41-50 of 67) with videos related to

Pageof 7
Sort By:
The Journal of Infection|December 29, 2021
Nasopharyngeal Microbiota as an early severity biomarker in COVID-19 hospitalised patientsMaria Paz Ventero, Oscar Moreno-Perez, Carmen Molina-Pardines, et al.
International Journal of Clinical Practice|July 6, 2021
Clinical Frailty Score vs Hospital Frailty Risk Score for predicting mortality and other adverse outcome in hospitalised patients with COVID-19: Spanish case seriesJose-Manuel Ramos-Rincon, Oscar Moreno-Perez, Hector Pinargote-Celorio, et al.
Plos One|March 23, 2021
Fatality and risk features for prognosis in COVID-19 according to the care approach - a retrospective cohort studyMariano Andrés, Jose-Manuel Leon-Ramirez, Oscar Moreno-Perez, et al.
Frontiers in Cardiovascular Medicine|November 7, 2022
Early carbohydrate antigen 125 as a mortality predictor in hospitalized patients with coronavirus disease 2019Oscar Moreno-Perez, Julio Nuñez, Miriam Sandin-Rollan, et al.
Frontiers in Pharmacology|October 26, 2023
A retrospective real-world study of early short-course remdesivir in non-hospitalized COVID-19 patients at high risk for progression: low rate of hospitalization or death, regardless of immunocompetence statusJosé Manuel Ramos-Rincón, Héctor Pinargote-Celorio, Jara Llenas-García, et al.
International Journal of Molecular Sciences|February 11, 2023
Transient Changes in the Plasma of Astrocytic and Neuronal Injury Biomarkers in COVID-19 Patients without Neurological SyndromesMatthew P Lennol, Nicholas J Ashton, Oscar Moreno-Pérez, et al.
The Journal of Infection|January 15, 2021
Post-acute COVID-19 syndrome. Incidence and risk factors: A Mediterranean cohort studyOscar Moreno-Pérez, Esperanza Merino, Jose-Manuel Leon-Ramirez, et al.
Plos One|June 15, 2018
Raltegravir plus abacavir/lamivudine in virologically suppressed HIV-1-infected patients: 48-week results of the KIRAL studyJesús Troya, Rocio Montejano, Pablo Ryan, et al.
Journal of the International AIDS Society|November 15, 2014
Dual therapy with darunavir/r plus etravirine is safe and effective as switching therapy in antiretroviral experienced HIV-patients. The BITER StudyJoaquín Portilla, Piedad Arazo, Josefa Crusells, et al.
Enfermedades Infecciosas Y Microbiologia Clinica|December 12, 2022
[Mild SARS-CoV-2 infection in vulnerable patients: implementation of a clinical pathway for early treatment]Héctor Pinargote-Celorio, Silvia Otero-Rodríguez, Pilar González-de-la-Aleja, et al.
Pageof 7

Showing results (41-50 of 67) with videos related to

Sort By:
Pageof 7
The Journal of Infection|December 29, 2021
Nasopharyngeal Microbiota as an early severity biomarker in COVID-19 hospitalised patientsMaria Paz Ventero, Oscar Moreno-Perez, Carmen Molina-Pardines, et al.
International Journal of Clinical Practice|July 6, 2021
Clinical Frailty Score vs Hospital Frailty Risk Score for predicting mortality and other adverse outcome in hospitalised patients with COVID-19: Spanish case seriesJose-Manuel Ramos-Rincon, Oscar Moreno-Perez, Hector Pinargote-Celorio, et al.
Plos One|March 23, 2021
Fatality and risk features for prognosis in COVID-19 according to the care approach - a retrospective cohort studyMariano Andrés, Jose-Manuel Leon-Ramirez, Oscar Moreno-Perez, et al.
Frontiers in Cardiovascular Medicine|November 7, 2022
Early carbohydrate antigen 125 as a mortality predictor in hospitalized patients with coronavirus disease 2019Oscar Moreno-Perez, Julio Nuñez, Miriam Sandin-Rollan, et al.
Frontiers in Pharmacology|October 26, 2023
A retrospective real-world study of early short-course remdesivir in non-hospitalized COVID-19 patients at high risk for progression: low rate of hospitalization or death, regardless of immunocompetence statusJosé Manuel Ramos-Rincón, Héctor Pinargote-Celorio, Jara Llenas-García, et al.
International Journal of Molecular Sciences|February 11, 2023
Transient Changes in the Plasma of Astrocytic and Neuronal Injury Biomarkers in COVID-19 Patients without Neurological SyndromesMatthew P Lennol, Nicholas J Ashton, Oscar Moreno-Pérez, et al.
The Journal of Infection|January 15, 2021
Post-acute COVID-19 syndrome. Incidence and risk factors: A Mediterranean cohort studyOscar Moreno-Pérez, Esperanza Merino, Jose-Manuel Leon-Ramirez, et al.
Plos One|June 15, 2018
Raltegravir plus abacavir/lamivudine in virologically suppressed HIV-1-infected patients: 48-week results of the KIRAL studyJesús Troya, Rocio Montejano, Pablo Ryan, et al.
Journal of the International AIDS Society|November 15, 2014
Dual therapy with darunavir/r plus etravirine is safe and effective as switching therapy in antiretroviral experienced HIV-patients. The BITER StudyJoaquín Portilla, Piedad Arazo, Josefa Crusells, et al.
Enfermedades Infecciosas Y Microbiologia Clinica|December 12, 2022
[Mild SARS-CoV-2 infection in vulnerable patients: implementation of a clinical pathway for early treatment]Héctor Pinargote-Celorio, Silvia Otero-Rodríguez, Pilar González-de-la-Aleja, et al.
Pageof 7